[Investigation of the toxicity of the antilipidaemic agent 2-[4-[2-[4-chlorobenzamido] ethyl] phenoxyl]-2-methyl-propionic acid (BM-15075)]
1984
Salom, L.
Application of Bezafibrate in rats causes pronounced hepatomegaly with histologically visible signs of hepatic cell hypertrophy with vacuolar degradation of cytoplasm and nucleus hypertrophy. Hepatomegaly is not accompanied by metamorphosis or acute necrosis of hepatic cells. Changes in the liver are accompanied by changes in the cortices of suprarenal and pituitary bodies. Equal doses of Bezafibrate are more efficient in male than in1650female rats. Liver dystrophy is proved by increased enzyme activity, rapid increase of bilirubin and urea and creatinine concentrations. Bezafibrate causes structural damages of renal tubules followed by increased sodium and potassium ions issue and increased leucocyte number. Bezafibrate applied in males causes significant weight increase of liver, suprarenal body, kidneys, thyroid gland, heart and pituitary body and only of liver and kidneys in females. Body weight of contaminated males decreases as we
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Unassigned data from Yugoslavia